Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 705564 (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design) and Food Effect on a Tablet Formulation of BI 705564 (Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Design) in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2017
At a glance
- Drugs BI 705564 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 17 Nov 2017 Planned number of patients changed from 88 to 92.
- 14 Nov 2017 Planned End Date changed from 18 Dec 2017 to 12 Feb 2018.
- 14 Nov 2017 Planned primary completion date changed from 18 Dec 2017 to 12 Feb 2018.